Phaseline

Companies › NeuroRx

NeuroRx: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NRX-101
D-cycloserine (NMDA co-agonist/glycine site modulator) + Lurasidone (5-HT and dopamine ant
GLRA1, HTR2APhase 2Treatment Resistant DepressionDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07227103NRX-101Phase 2Treatment Resistant DepressionPsychiatryDec 2027

Targets

GLRA1 (1) HTR2A (1)

Companies with the same targets

Pharmasoft Sedana Medical Cybin IRL COMPASS Pathways ACADIA Pharmaceuticals Vanda Pharmaceuticals Intra-Cellular Therapies Definium Therapeutics US Sichuan Kelun Pharmaceutical Boryung Pharmaceutical

Companies built like this

Cybin IRL Bazelet Nehushtan Autobahn Therapeutics atai Therapeutics Arialys Australia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.